Screening of potential donors for immunoglobulins M and G to new coronavirus infection

Abstract

This study presents the results of the examination of potential donors of blood and its components for immunoglobulins M and G to patients with coronavirus disease 2019 (COVID-19) living in St. Petersburg. A total of 6782 people aged 18−24 years were evaluated, which accounted for 2.07% of the region’s population (326 760 people) of this age group. The study was carried out in the spring and autumn of 2020. A negative result (absence of antibodies) was obtained in 93.5% of the participants. The rates of immunoglobulins M and M + G were 0.58% and 4.18%, respectively, in the spring and autumn. Moreover, the number of participants who had immunoglobulins M and G + M in the autumn period was four times higher than the indicators of the spring period, which indicated greater infection activities in the population during this period. This is most likely due to the active movement of the population in the summer. When comparing the rates of COVID-19 infection and the frequency of occurrence in donors of the same age, markers of human immunodeficiency virus 1 and 2 and hepatitis B and C in 2020 (0.024, 0.012 and 0.13%, respectively) indicate the urgency of the problem of donor selection during blood services, especially during a difficult epidemiological situation because of COVID-19. Along with organizational measures for the selection of donors (e.g., attracting individuals from organized groups in which there are no signs of an unfavorable epidemiological situation to donation), mandatory testing of potential donors for immunoglobulins M and G should be considered.

Keywords

virus / donors / immunoglobulins / coronavirus infection / plasma / epidemic / antibodies

References

[1] Supotnickij MV. Novyj koronavirus SARS-CoV-2 v aspekte global’noj jepidemiologii koronavirusnyh infekcij. Vestnik vojsk RHB zashhity. 2020;1(4):32−65. (In Russ.). DOI:10.35825/2587-5728-2020-4-1-32-65

[2] Супотницкий М.В. Новый коронавирус SARS-CoV-2 в аспекте глобальной эпидемиологии коронавирусных инфекций // Вестник войск РХБ защиты. 2020. № 1 (4). С. 32−65. DOI: 10.35825/2587-5728-2020-4-1-32-65

[3] Tolstykh VV, Yampol’skii SM. Vliyanie pandemii koronavirusa COVID-19 na deyatel’nost’ vooruzhennykh sil Rossiiskoi Federatsii i inostrannykh armii po obespecheniyu oboronosposobnosti gosudarstva. Natsional’naya bezopasnost i strategicheskoe planirovanie. 2020;3(31):30−36. (In Russ.).

[4] Толстых В.В., Ямпольский С.М. Влияние пандемии коронавируса СOVID-19 на деятельность Вооруженных сил Российской Федерации и иностранных армий по обеспечению обороноспособности государства // Национальная безопасность и стратегическое планирование. 2020. № 3 (31). С. 30−36.

[5] Upravlenie Federal`noj sluzhby gosudarstvennoj statistiki po g. Sankt-Peterburgu i Leningradskoj oblasti (Petrostat). Vozrastno-polovoj sostav naseleniya Sankt-Peterburga na 1 yanvarya 2020 goda. Statisticheskiy byulleten. 2020;(VS-140/1245):5–10. (In Russ.).

[6] Управление Федеральной службы государственной статистики по г. Санкт-Петербургу и Ленинградской области (Петростат). Возрастно-половой состав населения Санкт-Петербурга на 1 января 2020 года // Статистический бюллетень. 2020. № ВС-140/1245. С. 5–10.

[7] Bloch E, Shoham S, Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation. 2020;6(103):2757−2765. DOI: 10.1172/JCI138745

[8] Bloch E., Shoham S., Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19 // Journal of Clinical Investigation. 2020. Vol. 6, No. 103. P. 2757−2765. DOI: 10.1172/JCI138745

[9] Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398−400. DOI: 10.1016/S1473-3099(20)30141-9

[10] Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19 // Lancet Infect. Dis. 2020. Vol. 20, No. 4. P. 398−400. DOI: 10.1016/S1473-3099(20)30141-9

RIGHTS & PERMISSIONS

Romashova Y.E., Vilyaninov V.N., Belgesov N.V., Kaleko S.P.